HIV

Latest News


Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

This discussion focuses on how to address barriers and disparities as obstacles to using PrEP, with a focus on USPSTF PrEP guidelines and ACA Part 47 for payers and providers.

Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

CME Content


The president has released his budget for fiscal year (FY) 2020, which calls for converting Medicaid to a system of block grants and requiring all able-bodied Medicaid recipients to hold a job or perform community service. The $87.1 billion allocated to HHS, a 12% cut, would include increases to federal HIV funding, but drops in global funding, as well as cuts to the National Institutes of Health (NIH).

This week, the top managed care news included Scott Gottlieb, MD, resigning as FDA commissioner; Eli Lilly offering a discounted version of Humalog; and a second patient reported cured of HIV.

Kaiser Permanente will waive annual tuition for the first 5 classes of its new medical school, following a similar move by the New York University School of Medicine; menopause is typically thought of in terms of the end of fertility, but more attention is being paid to the effects of the lack of estrogen on the brain; a federal judge has ordered the US Air Force to temporarily stop discharging service members who are HIV-positive.

This week, the top managed care news included President Trump's State of the Union address highlighting healthcare; HHS Secretary Alex Azar taking on drug rebates; and physicians asking Congress to fully implement the HITECH Act.

While President Trump's State of the Union address is not finalized, he may plan to unveil a promise to end HIV transmission in America by 2030; a federal judge dismissed a lawsuit brought by Maryland that claimed the Trump administration is failing to enforce the Affordable Care Act; new cystic fibrosis (CF) treatments targeting the genetic mutations that cause the disease help about 90% of patients, meaning that 10% are still waiting for a cutting-edge therapy.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo